FY2027 Earnings Estimate for Kamada Issued By HC Wainwright

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at HC Wainwright lowered their FY2027 EPS estimates for shares of Kamada in a report released on Friday, August 14th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $0.56 per share for the year, down from their previous forecast of $0.64. The consensus estimate for Kamada’s current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for Kamada’s FY2028 earnings at $0.69 EPS and FY2029 earnings at $0.74 EPS.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%.

A number of other equities analysts have also recently issued reports on the company. Benchmark restated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Weiss Ratings lowered Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Wall Street Zen raised Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Finally, William Blair set a $15.00 price objective on Kamada in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $13.00.

Kamada Stock Performance

NASDAQ KMDA opened at $7.76 on Monday. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The business’s fifty day moving average is $7.23 and its two-hundred day moving average is $7.95. The stock has a market capitalization of $446.28 million, a P/E ratio of 20.42, a P/E/G ratio of 0.67 and a beta of 0.86.

Hedge Funds Weigh In On Kamada

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new position in shares of Kamada in the 1st quarter valued at about $206,000. NewEdge Advisors LLC grew its position in Kamada by 119.9% during the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 28,165 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in Kamada during the first quarter valued at approximately $497,000. Jane Street Group LLC acquired a new position in Kamada in the 1st quarter valued at approximately $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Kamada in the 2nd quarter valued at approximately $472,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Cuts Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, September 17th. Investors of record on Thursday, August 27th will be paid a $0.17 dividend. This represents a yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th. Kamada’s dividend payout ratio is currently 50.00%.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.